BR112015023404A8 - composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos - Google Patents

composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos Download PDF

Info

Publication number
BR112015023404A8
BR112015023404A8 BR112015023404A BR112015023404A BR112015023404A8 BR 112015023404 A8 BR112015023404 A8 BR 112015023404A8 BR 112015023404 A BR112015023404 A BR 112015023404A BR 112015023404 A BR112015023404 A BR 112015023404A BR 112015023404 A8 BR112015023404 A8 BR 112015023404A8
Authority
BR
Brazil
Prior art keywords
precursors
age
pharmaceutical compositions
end product
advanced glycation
Prior art date
Application number
BR112015023404A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015023404A2 (pt
Inventor
T Papoulis Andrew
Besev Magnus
Dhal Pradeep
J Miller Robert
Randall Holmes-Farley Stephen
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112015023404A2 publication Critical patent/BR112015023404A2/pt
Publication of BR112015023404A8 publication Critical patent/BR112015023404A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
BR112015023404A 2013-03-15 2014-03-12 composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos BR112015023404A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (2)

Publication Number Publication Date
BR112015023404A2 BR112015023404A2 (pt) 2017-07-18
BR112015023404A8 true BR112015023404A8 (pt) 2019-12-03

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023404A BR112015023404A8 (pt) 2013-03-15 2014-03-12 composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos

Country Status (24)

Country Link
US (2) US20160024233A1 (https=)
EP (1) EP2968403A1 (https=)
JP (4) JP2016512830A (https=)
KR (1) KR20150130492A (https=)
CN (1) CN105188718A (https=)
AR (1) AR095593A1 (https=)
AU (2) AU2014235500A1 (https=)
BR (1) BR112015023404A8 (https=)
CA (1) CA2906501A1 (https=)
CL (1) CL2015002624A1 (https=)
CR (1) CR20150545A (https=)
DO (1) DOP2015000221A (https=)
EA (1) EA201591733A1 (https=)
HK (1) HK1220607A1 (https=)
IL (1) IL241406A0 (https=)
MA (1) MA38487A1 (https=)
MX (1) MX2015012843A (https=)
PE (1) PE20151766A1 (https=)
PH (1) PH12015502019A1 (https=)
SG (2) SG10201707590XA (https=)
TN (1) TN2015000390A1 (https=)
TW (1) TW201521744A (https=)
UY (1) UY35441A (https=)
WO (1) WO2014150873A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
CN111405870A (zh) * 2017-08-31 2020-07-10 西托索尔本茨公司 从体液中降低晚期糖基化终末产物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CA2444046C (en) * 2001-04-18 2011-06-07 Steven K. Burke Use of colesevelam in reducing serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
AU2005214971A1 (en) * 2004-02-17 2005-09-01 Dynamis Therapeutics, Inc. Fructoseamine 3 kinase and the formation of collagen and elastin
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
WO2011106542A2 (en) * 2010-02-24 2011-09-01 Relypsa, Inc. Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
IL241406A0 (en) 2015-11-30
KR20150130492A (ko) 2015-11-23
EP2968403A1 (en) 2016-01-20
WO2014150873A1 (en) 2014-09-25
JP2016512830A (ja) 2016-05-09
CA2906501A1 (en) 2014-09-25
SG10201707590XA (en) 2017-11-29
US20180265613A1 (en) 2018-09-20
PE20151766A1 (es) 2015-12-11
PH12015502019A1 (en) 2016-01-11
EA201591733A1 (ru) 2016-01-29
US20160024233A1 (en) 2016-01-28
JP2018135365A (ja) 2018-08-30
MA38487A1 (fr) 2017-12-29
TW201521744A (zh) 2015-06-16
JP2022037143A (ja) 2022-03-08
DOP2015000221A (es) 2015-12-15
MX2015012843A (es) 2016-08-08
UY35441A (es) 2014-10-31
CR20150545A (es) 2015-12-01
BR112015023404A2 (pt) 2017-07-18
HK1220607A1 (zh) 2017-05-12
AR095593A1 (es) 2015-10-28
TN2015000390A1 (en) 2017-01-03
CL2015002624A1 (es) 2016-03-11
JP2020055850A (ja) 2020-04-09
CN105188718A (zh) 2015-12-23
AU2019201259A1 (en) 2019-03-14
SG11201506413PA (en) 2015-09-29
AU2014235500A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
EA201990043A1 (ru) Антибактериальные соединения
EA201890204A1 (ru) Антибактериальные соединения
BR112015026830A8 (pt) composto, composição farmacêutica, combinação, produto, uso de um composto, e, método para profilaxia ou tratamento de um estado de doença ou condição
MX340985B (es) Compuestos de n-heteroarilo.
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112014029762A2 (pt) composição contendo n-metil-n-acilglucamina
EA201591166A1 (ru) Ингибиторы аутотаксина
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112016007536A8 (pt) compostos, composições e utilizações correspondentes, para a prevenção e/ou o tratamento de dislipidemias
MX374129B (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos.
BR112018000632A8 (pt) Moléculas de anticorpo que ligam a cd79
PH12015502275B1 (en) Therapuetic uses of empagliflozin
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
AU2017261919A1 (en) Fat and medical uses thereof
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
BR112015023404A8 (pt) composições farmacêuticas contendo sequestrantes de precursores de produto final de glicação avançada (age) e uso dos mesmos
BR112015019084A2 (pt) métodos para aumentar o rendimento das culturas
EA201590782A1 (ru) Оксирановые амины
EA201501177A1 (ru) Фармацевтические композиции
BR112016002176A2 (pt) novos compostos de indazol e um processo para a sua preparação
ES2526935A1 (es) Compuestos para el tratamiento de infecciones por Leishmania

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements